On this page

Clobetasol Propionate Cream USP, 0.05%

Prescription ANDA TE AB1 Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Clobetasol Propionate Cream USP, 0.05% Clobetasol Propionate Cream USP, 0.05%
Generic name
Clobetasol Propionate Cream USP, 0.05%
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
A-S Medication Solutions
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
7
Packages
16
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Clobetasol Propionate .5 mg/g 861490 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
23

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
212982
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 28, 2020
Sponsor
ENCUBE
Products on application
1
Submissions recorded
1
Products approved under application 212982.
Product Trade name Form Strength Ingredient Status TE Flags
212982-001 CLOBETASOL PROPIONATE CREAM CLOBETASOL PROPIONATE Prescription AB1 RS

Therapeutic equivalence

Source: Orange Book
TE code
AB1
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 212982.
Type No. Action Status Date Review
Original application 1 Approved August 28, 2020 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260909). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260909 HUMAN PRESCRIPTION DRUG · 20260824 HUMAN PRESCRIPTION DRUG · 20260709 HUMAN PRESCRIPTION DRUG · 20240909

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Clobetasol propionate cream USP, 0.05% is super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g /week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply a thin layer of clobetasol propionate cream to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE ). Clobetasol propionate cream is super- high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g / week should not be used . As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol propionate cream should not be used with occlusive dressings. Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS ) have been treated with clobetasol propionate cream, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Clobetasol propionate cream USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: In controlled clinical trials, the most frequent adverse reactions reported for clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin. Cushing's syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Clobetasol Propionate Cream USP contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Chemically, clobetasol propionate is (11β, 16β)-21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione, and it has the following structural formula: Clobetasol propionate has the molecular formula C 25 H 32 ClFO 5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water. Clobetasol propionate cream USP, 0.05% contains clobetasol propionate 0.5 mg/g in a cream base of propylene glycol, mono- and di-glycerides, cetostearyl alcohol, stearoyl macrogolglycerides, white wax, chlorocresol, sodium citrate, anhydrous citric acid, and purified water. structure.jpg

OVERDOSAGE: Topically applied clobetasol propionate cream can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Clobetasol Propionate Cream USP, 0.05% is supplied in 15 g tube (NDC 21922-016-04) 30 g tube (NDC 21922-016-05) 45 g tube (NDC 21922-016-06) 60 g tube (NDC 21922-016-07) Store cream between 15° and 30°C (59°-86°F). Clobetasol propionate cream should not refrigerated. Made in Italy, formulated in India. Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. OR Manufacture by: Encube Ethicals Pvt. Ltd. Plot No. 113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202 Durham, NC 27713 USA Rev: 12/23

Adverse event reports

Source: openFDA FAERS
10,472
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CLOBETASOL PROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-5979-0 50090-5979 A-S Medication Solutions 30 g in 1 TUBE (50090-5979-0) May 6, 2022
50090-7392-0 50090-7392 A-S Medication Solutions 15 g in 1 TUBE (50090-7392-0) October 23, 2024
71335-2821-1 71335-2821 Bryant Ranch Prepack 60 g in 1 TUBE (71335-2821-1) October 22, 2025
72162-2300-2 72162-2300 Bryant Ranch Prepack 15 g in 1 TUBE (72162-2300-2) October 1, 2020
72162-2300-3 72162-2300 Bryant Ranch Prepack 30 g in 1 TUBE (72162-2300-3) October 1, 2020
72162-2300-4 72162-2300 Bryant Ranch Prepack 45 g in 1 TUBE (72162-2300-4) October 1, 2020
72162-2300-6 72162-2300 Bryant Ranch Prepack 60 g in 1 TUBE (72162-2300-6) October 1, 2020
21922-016-04 21922-016 Encube Ethicals, Inc. 15 g in 1 TUBE (21922-016-04) October 1, 2020
21922-016-05 21922-016 Encube Ethicals, Inc. 30 g in 1 TUBE (21922-016-05) October 1, 2020
21922-016-06 21922-016 Encube Ethicals, Inc. 45 g in 1 TUBE (21922-016-06) October 1, 2020
21922-016-07 21922-016 Encube Ethicals, Inc. 60 g in 1 TUBE (21922-016-07) October 1, 2020
72603-323-01 72603-323 Northstar Rx LLC 15 g in 1 TUBE (72603-323-01) November 1, 2024
72603-323-02 72603-323 Northstar Rx LLC 30 g in 1 TUBE (72603-323-02) November 1, 2024
72603-323-03 72603-323 Northstar Rx LLC 45 g in 1 TUBE (72603-323-03) November 1, 2024
72603-323-04 72603-323 Northstar Rx LLC 60 g in 1 TUBE (72603-323-04) November 1, 2024
70518-4374-0 70518-4374 REMEDYREPACK INC. 30 g in 1 TUBE (70518-4374-0) June 27, 2025
50090-5979 50090-5979 A-S Medication Solutions — October 1, 2020
50090-7392 50090-7392 A-S Medication Solutions — October 1, 2020
71335-2821 71335-2821 Bryant Ranch Prepack — October 1, 2020
72162-2300 72162-2300 Bryant Ranch Prepack — October 1, 2020
21922-016 21922-016 Encube Ethicals, Inc. — October 1, 2020
72603-323 72603-323 Northstar Rx LLC — November 1, 2024
70518-4374 70518-4374 REMEDYREPACK INC. — June 27, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.